文献速递头颈与中枢神经肿瘤

放疗联合化疗在鼻咽癌患者中的作用(MAC-NPC):更新的个体患者数据网络荟萃分析

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis.
PubMed 文献 · Lancet Oncol · 2023-01-01

该更新的个体患者数据网络荟萃分析纳入28项试验、8214例非转移性鼻咽癌患者,比较放疗联合不同化疗方案的生存获益。结果显示,与单纯化放疗相比,诱导化疗联合化放疗或化放疗后辅助化疗可改善总生存。

要点

  • 含紫杉类诱导化疗后化放疗的总生存获益最高(HR 0.75,p评分92%)。
  • 不含紫杉类诱导化疗后化放疗(HR 0.81)及化放疗后辅助化疗(HR 0.88)亦显示获益。
  • 与单纯化放疗相比,在化放疗基础上增加诱导或辅助化疗可改善总生存。

核心结论

  • 在化放疗基础上增加诱导化疗或辅助化疗,较单纯化放疗改善鼻咽癌患者的总生存。

研究设计与样本

  • 个体患者数据网络荟萃分析,纳入28项试验、8214例非转移性鼻咽癌患者,于1988年1月1日至2016年12月31日入组,中位随访7.6年(IQR 6.2-13.3)。

主要发现

  • 与化放疗相比,含紫杉类诱导化疗后化放疗的HR为0.75(95%CI 0.59-0.96),p评分92%。
  • 与化放疗相比,不含紫杉类诱导化疗后化放疗的HR为0.81(95%CI 0.69-0.95),p评分87%。
  • 与化放疗相比,化放疗后辅助化疗的HR为0.88(95%CI 0.75-1.04),p评分72%。
  • 异质性检验p=0.18,不一致性检验p=0.10(临界)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The meta-analysis of chemotherapy for nasopharynx carcinoma (MAC-NPC) collaborative group previously showed that the addition of adjuvant chemotherapy to concomitant chemoradiotherapy had the highest survival benefit of the studied treatment regimens in nasopharyngeal carcinoma. Due to the publication of new trials on induction chemotherapy, we updated the network meta-analysis. METHODS: For this individual patient data network meta-analysis, trials of radiotherapy with or without chemotherapy in patients with non-metastatic nasopharyngeal carcinoma that completed accrual before Dec 31, 2016, were identified and updated individual patient data were obtained. Both general databases (eg, PubMed and Web of Science) and Chinese medical literature databases were searched. Overall survival was the primary endpoint. A frequentist network meta-analysis approach with a two-step random effect stratified by trial based on hazard ratio Peto estimator was used. Global Cochran Q statistic was used to assess homogeneity and consistency, and p score to rank treatments, with higher scores indicating higher benefit therapies. Treatments were grouped into the following categories: radiotherapy alone, induction chemotherapy followed by radiotherapy, induction chemotherapy without taxanes followed by chemoradiotherapy, induction chemotherapy with taxanes followed by chemoradiotherapy, chemoradiotherapy, chemoradiotherapy followed by adjuvant chemotherapy, and radiotherapy followed by adjuvant chemotherapy. This study is registered with PROSPERO, CRD42016042524. FINDINGS: The network comprised 28 trials and included 8214 patients (6133 [74·7%] were men, 2073 [25·2%] were women, and eight [0·1%] had missing data) enrolled between Jan 1, 1988, and Dec 31, 2016. Median follow-up was 7·6 years (IQR 6·2-13·3). There was no evidence of heterogeneity (p=0·18), and inconsistency was borderline (p=0·10). The three treatments with the highest benefit for overall survival were induction chemotherapy with taxanes followed by chemoradiotherapy (hazard ratio 0·75; 95% CI 0·59-0·96; p score 92%), induction chemotherapy without taxanes followed by chemoradiotherapy (0·81; 0·69-0·95; p score 87%), and chemoradiotherapy followed by adjuvant chemotherapy (0·88; 0·75-1·04; p score 72%), compared with concomitant chemoradiotherapy (p score 46%). INTERPRETATION: The inclusion of new trials modified the conclusion of the previous network meta-analysis. In this updated network meta-analysis, the addition of either induction chemotherapy or adjuvant chemotherapy to chemoradiotherapy improved overall survival over chemoradiotherapy alone in nasopharyngeal carcinoma. FUNDING: Institut National du Cancer and Ligue Nationale Contre le Cancer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Petit C, Lee A, Ma J, et al. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 2023. PMID: 37269842. doi:10.1016/S1470-2045(23)00163-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。